MetaVia Hits Key Dose Milestones in Obesity Drug Trial
Event summary
- MetaVia completed dose titration in its Phase 1 Part 3 study of DA-1726, with all patients reaching the highest planned doses of 48 mg and 64 mg.
- DA-1726 demonstrated up to 9.1% mean weight loss after eight weeks in a Phase 1 trial, with no evidence of plateau.
- Vanoglipel (DA-1241) showed synergistic effects with resmetirom in MASH and metformin in type 2 diabetes in preclinical data.
- MetaVia reported a net loss of $5.3 million for Q2 2026, up from $4.0 million in Q2 2025.
The big picture
MetaVia's progress with DA-1726 and vanoglipel underscores the competitive landscape in cardiometabolic disease treatments. The company is positioning itself as a key player in obesity and MASH therapies, but must navigate increasing R&D costs and regulatory hurdles to maintain momentum.
What we're watching
- Clinical Efficacy
- Whether DA-1726's 16-week study will confirm its potential as a best-in-class obesity treatment.
- Regulatory Pathway
- The timeline for MetaVia's End-of-Phase 2 meeting with the FDA to discuss vanoglipel's development.
- Financial Sustainability
- How long MetaVia's current cash position will last given its rising R&D expenses.
Related topics